Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2006

View Archived Issues

Pegaptanib binding analyzed, revealing mechanism of action

Adverse event analysis raises questions about mifepristone

Study suggests survival benefit with efaproxiral in brain metastases

Targeting TREK/TRAAK K+ channels for neuroprotection in stroke

Guidant deems Boston Scientific's offer superior to that of Johnson & Johnson

Aegera cleared for phase I study of AEG-33783 for peripheral neuropathies

Sepracor makes additional equity investment in Acadia Pharmaceuticals

Second p38 kinase inhibitor begins phase I trials from Pharmacopeia partnership

Roche and Trimeris to codevelop two next-generation HIV fusion inhibitor peptides

ARRY-334543 begin phase I study in cancer patients

FDA extends Myozyme review period

Phase II trial examines Symadex in relapsed metastatic colorectal cancer patients

Series A funds to support development of newly inlicensed compound at Ocera

Conclusion of patient follow-up in Canadian phase I Reolysin study

Theregen receives funding for Anginera development

PharmaFrontiers acquires autologous T-cell vaccine rights for rheumatoid arthritis

Inovio and Tripep sign agreement for HCV vaccine development

Technosphere Insulin produces improved glycemic control

Plavix sNDA for STEMI granted priority review

CCR5 plays opposite roles in HIV and WNV infection

Novel analgesic agents disclosed in recent patents

Recent patents describe novel antiinfective agents

Emisphere discloses novel drug delivery agents

Novartis prepares and tests novel agents for transplant rejection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...